1-4 of 4
Christopher K Arthur, MBBS, FRACP, FRCPA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Naranie Shanmuganathan, MBBS FRACP FRCPA, Andrew Grigg, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MBBS FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MD, Agnes S. M. Yong, MD PhD, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 2926.
https://doi.org/10.1182/blood-2019-125740
Published: 2019
Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG
Journal: Blood
Blood (2012) 120 (21): 3771.
https://doi.org/10.1182/blood.V120.21.3771.3771
Published: 2012
Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2011) 118 (21): 451.
https://doi.org/10.1182/blood.V118.21.451.451
Published: 2011
Journal Articles

High Response Rate in Patients with De-Novo or Relapsed/Refractory Acute Myeloid Leukemia Using a Novel Strategy of Low-Dose, Prolonged Administration of Cytarabine and Thioguanine in Combination with Filgrastim in the Ambulatory Setting: A Single-Center, Retrospective Study

Christopher K Arthur, MBBS, FRACP, FRCPA, Brandon Aubrey, MB BS, Matthew Greenwood, MD, FRCPA, FRACP, Keith Fay, MBChB, Luke Coyle, MBBS, FRACP, FRCPA, Eunice Liu, MB BS, Christopher Ward, MB, CHB, PhD, Garry Soo, Naomi Mackinlay, MB BS FRACP FRCPA, William s Stevenson, MBBS, PhD
Journal: Blood
Blood (2011) 118 (21): 2624.
https://doi.org/10.1182/blood.V118.21.2624.2624
Published: 2011